EP4135695A4 - Methods for treating cytokine release syndrome - Google Patents

Methods for treating cytokine release syndrome Download PDF

Info

Publication number
EP4135695A4
EP4135695A4 EP21788245.5A EP21788245A EP4135695A4 EP 4135695 A4 EP4135695 A4 EP 4135695A4 EP 21788245 A EP21788245 A EP 21788245A EP 4135695 A4 EP4135695 A4 EP 4135695A4
Authority
EP
European Patent Office
Prior art keywords
methods
cytokine release
release syndrome
treating cytokine
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP21788245.5A
Other languages
German (de)
French (fr)
Other versions
EP4135695A1 (en
Inventor
Mark R. Bray
Jacqueline M. Mason
Xin Wei
Gordon DUNCAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
University of Health Network
Original Assignee
University Health Network
University of Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network, University of Health Network filed Critical University Health Network
Publication of EP4135695A1 publication Critical patent/EP4135695A1/en
Publication of EP4135695A4 publication Critical patent/EP4135695A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP21788245.5A 2020-04-13 2021-04-12 Methods for treating cytokine release syndrome Withdrawn EP4135695A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063009059P 2020-04-13 2020-04-13
US202063022956P 2020-05-11 2020-05-11
PCT/CA2021/050483 WO2021207828A1 (en) 2020-04-13 2021-04-12 Methods for treating cytokine release syndrome

Publications (2)

Publication Number Publication Date
EP4135695A1 EP4135695A1 (en) 2023-02-22
EP4135695A4 true EP4135695A4 (en) 2024-05-15

Family

ID=78083464

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21788245.5A Withdrawn EP4135695A4 (en) 2020-04-13 2021-04-12 Methods for treating cytokine release syndrome

Country Status (12)

Country Link
US (1) US20230144869A1 (en)
EP (1) EP4135695A4 (en)
JP (1) JP2023522618A (en)
KR (1) KR20230018365A (en)
CN (1) CN115867275A (en)
AU (1) AU2021257439A1 (en)
BR (1) BR112022020814A2 (en)
CA (1) CA3175420A1 (en)
IL (1) IL297314A (en)
MX (1) MX2022012812A (en)
TW (1) TW202203917A (en)
WO (1) WO2021207828A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
BR112022025381A2 (en) 2020-06-11 2023-01-24 Provention Bio Inc METHODS AND COMPOSITIONS TO PREVENT TYPE 1 DIABETES
CN115803026A (en) * 2020-06-26 2023-03-14 瓦伦塔有限责任公司 Use of glutarimide derivatives for the treatment of diseases associated with abnormal interleukin-6 activity
AU2020459746A1 (en) 2020-07-20 2023-03-16 Deka Biosciences, Inc. Dual cytokine fusion proteins comprising IL-10
CN118525026A (en) * 2022-01-27 2024-08-20 西藏海思科制药有限公司 Compound for inhibiting or degrading HPK1 kinase and application thereof in medicine
US20230340052A1 (en) * 2022-02-22 2023-10-26 Deka Biosciences, Inc. Method of reducing bispecific t cell engager or chimeric antigen receptor t cell mediated cytokine release syndrome using interleukins-4, -10, or a fusion protein thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018383A2 (en) * 2000-09-01 2002-03-07 Chiron Corporation Aza heterocyclic derivatives and their therapeutic use
WO2003104203A1 (en) * 2002-06-07 2003-12-18 Cortical Pty Ltd Therapeutic molecules and methods-1
WO2006102191A1 (en) * 2005-03-24 2006-09-28 Avanir Pharmaceuticals Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2872555T3 (en) * 2015-06-25 2021-11-02 Univ Health Network HPK1 inhibitors and methods of using them
CN109721620B (en) * 2017-10-27 2022-05-13 药捷安康(南京)科技股份有限公司 HPK1 inhibitors and uses thereof
WO2020135483A1 (en) * 2018-12-26 2020-07-02 Janssen Pharmaceutica Nv Thienopyridinone compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002018383A2 (en) * 2000-09-01 2002-03-07 Chiron Corporation Aza heterocyclic derivatives and their therapeutic use
WO2003104203A1 (en) * 2002-06-07 2003-12-18 Cortical Pty Ltd Therapeutic molecules and methods-1
WO2006102191A1 (en) * 2005-03-24 2006-09-28 Avanir Pharmaceuticals Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2021207828A1 *

Also Published As

Publication number Publication date
CA3175420A1 (en) 2021-10-21
US20230144869A1 (en) 2023-05-11
CN115867275A (en) 2023-03-28
JP2023522618A (en) 2023-05-31
KR20230018365A (en) 2023-02-07
WO2021207828A1 (en) 2021-10-21
BR112022020814A2 (en) 2022-11-29
EP4135695A1 (en) 2023-02-22
AU2021257439A1 (en) 2022-12-15
IL297314A (en) 2022-12-01
MX2022012812A (en) 2023-01-30
TW202203917A (en) 2022-02-01

Similar Documents

Publication Publication Date Title
EP4135695A4 (en) Methods for treating cytokine release syndrome
EP3846796A4 (en) Methods of treating cytokine release syndrome
EP4086346A4 (en) Method for treating usher syndrome and composition thereof
EP3615010A4 (en) Methods for treating dravet syndrome
EP3359677A4 (en) Compositions and methods for treating fragile x syndrome and related syndromes
EP3710016A4 (en) Methods and compositions for alleviating cytokine release syndrome
EP3758714A4 (en) Methods and compositions for treating angelman syndrome
EP3990221A4 (en) Advanced holding apparatus
EP4100419A4 (en) Methods for the treatment of hunter syndrome
EP3768281A4 (en) Compositions and methods for t-cell and cytokine activation
EP3931336A4 (en) Compositions and methods for treating laminopathies
EP3932056A4 (en) Method and apparatus for intra-prediction
EP3858817A4 (en) Method for producing amidate compound, and amidate compound
IL304502A (en) Compositions and methods for treating cytokine release syndrome
IL277993A (en) Kit, composition and combination therapy for fragile x syndrome
EP4125894A4 (en) Methods for treating cytokine storm syndrome and related diseases
EP3936643A4 (en) Method and apparatus for producing sic substrate
EP3952851A4 (en) Compounds and methods for treating inflammatory disorders
EP3782625A4 (en) Agent for improving cytokine release syndrome, etc
EP4022072A4 (en) Compositions and methods for treating viral infections
EP3908575A4 (en) Alk5 inhibitors for treating myelodysplastic syndrome
EP3957071A4 (en) Wavefront parallel processing for tile, brick, and slice
EP3928910A4 (en) Method for manufacturing rail, and rail
EP3908334A4 (en) Improved method and compositions for surface treatment
EP4192461A4 (en) Method for treatment of cytokine release syndrome

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20221111

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230511

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40084703

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20240410

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/496 20060101ALI20240405BHEP

Ipc: A61K 31/4365 20060101ALI20240405BHEP

Ipc: C07D 495/04 20060101ALI20240405BHEP

Ipc: A61P 37/02 20060101ALI20240405BHEP

Ipc: A61K 31/4436 20060101AFI20240405BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20240529